{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:06:02Z","timestamp":1791295562158,"version":"4.1.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1097\/bor.0000000000000096","type":"journal-article","created":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T17:08:42Z","timestamp":1406048922000},"page":"520-527","source":"Crossref","is-referenced-by-count":73,"title":["Advances in the understanding and treatment of systemic complications in Sj\u00f6gren's syndrome"],"prefix":"10.1097","volume":"26","author":[{"given":"Pilar","family":"Brito-Zer\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Ramos-Casals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210128","doi-asserted-by":"crossref","first-page":"e3821","DOI":"10.1136\/bmj.e3821","article-title":"Primary Sjogrens syndrome.","volume":"344","author":"Ramos-Casals","year":"2012","journal-title":"BMJ"},{"key":"R2-9-20210128","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/acr.22115","article-title":"Epidemiology of primary Sjogrens syndrome in a French multiracialmultiethnic area.","volume":"66","author":"Maldini","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R3-9-20210128","doi-asserted-by":"crossref","first-page":"e003569","DOI":"10.1136\/bmjopen-2013-003569","article-title":"Primary Sjogrens syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality.","volume":"3","author":"Nannini","year":"2013","journal-title":"BMJ Open"},{"key":"R4-9-20210128","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/acr.21591","article-title":"Sjogrens International Collaborative Clinical Alliance (SICCA) Research GroupsAmerican College of Rheumatology classification criteria for Sjogrens syndrome: a data-driven, expert consensus approach in the Sjogrens International Collaborative Clinical Alliance cohort.","volume":"64","author":"Shiboski","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R5-9-20210128","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2012-202565","article-title":"Classification criteria for Sjogrens syndrome: we actually need to definitively resolve the long debate on the issue.","volume":"72","author":"Vitali","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R6-9-20210128","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/ar4514","article-title":"Level of agreement between 2002 American-European Consensus Group and 2012 American College of Rheumatology classification criteria for Sjogrens syndrome and reasons for discrepancies.","volume":"16","author":"Cornec","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R7-9-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2013-203845","article-title":"Comparison of the American-European Consensus Group Sjogrens syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort.","volume":"73","author":"Rasmussen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R8-9-20210128","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1136\/annrheumdis-2013-205076","article-title":"The classification criteria for Sjogrens syndrome: issues for their improvement from the study of a large Italian cohort of patients.","volume":"73","author":"Quartuccio","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R9-9-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2013-203953","article-title":"Classification criteria for Sjogrens syndrome: nothing ever stands still!.","volume":"73","author":"Bowman","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R10-9-20210128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaut.2013.12.010","article-title":"Outcome measures for primary Sjogrens syndrome: a comprehensive review.","volume":"51C","author":"Seror","year":"2014","journal-title":"J Autoimmun"},{"key":"R11-9-20210128","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/ket349","article-title":"SS Study Group; Autoimmune Diseases Study Group (GEAS) of the Spanish Society of Internal Medicine (SEMI)Systemic involvement in primary Sjogrens syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry).","volume":"53","author":"Ramos-Casals","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R12-9-20210128","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/acr.21991","article-title":"European league against Rheumatism Sjogrens syndrome disease activity index and European league against Rheumatism Sjogrens syndrome patient-reported index: a complete picture of primary Sjogrens syndrome patients.","volume":"65","author":"Seror","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R13-9-20210128","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/annrheumdis-2013-203736","article-title":"EULAR Sjogrens Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial.","volume":"73","author":"Moerman","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R15-9-20210128","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/rheumatology\/ket427","article-title":"Primary Sjogrens syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients.","volume":"53","author":"Baldini","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R16-9-20210128","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","article-title":"Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogrens syndrome.","volume":"46","author":"Ioannidis","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R17-9-20210128","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2012-202863","article-title":"UK primary Sjogrens Syndrome RegistryHealth-related utility values of patients with primary Sjogrens syndrome and its predictors.","volume":"73","author":"Lendrem","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R19-9-20210128","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/acr.21956","article-title":"Pain severity and neuropathic pain symptoms in primary Sjogrens syndrome: a comparison study of seropositive and seronegative Sjogrens syndrome patients.","volume":"65","author":"Segal","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R20-9-20210128","first-page":"349","article-title":"Lower prevalence of extra-glandular manifestations and anti-SSB antibodies in patients with primary Sjogrens syndrome and widespread pain: evidence for a relatively benign subset.","volume":"32","author":"Ter Borg","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"R21-9-20210128","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/0961203313515764","article-title":"Annular erythema in primary Sjogrens syndrome: description of 43 non-Asian cases.","volume":"23","author":"Brito-Zeron","year":"2014","journal-title":"Lupus"},{"key":"R22-9-20210128","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/rheumatology\/kes311","article-title":"Clinical pulmonary involvement in primary Sjogrens syndrome: prevalence, quality of life and mortality: a retrospective study based on registry data.","volume":"52","author":"Palm","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"R23-9-20210128","doi-asserted-by":"crossref","first-page":"e73774","DOI":"10.1371\/journal.pone.0073774","article-title":"Prognostic factors in interstitial lung disease associated with primary Sjogrens syndrome: a retrospective analysis of 33 pathologically-proven cases.","volume":"8","author":"Enomoto","year":"2013","journal-title":"PLoS One"},{"key":"R24-9-20210128","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1002\/art.38100","article-title":"Clinically significant renal involvement in primary Sjogrens syndrome: clinical presentation and outcome.","volume":"65","author":"Goules","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R25-9-20210128","first-page":"103","article-title":"Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjogrens syndrome.","volume":"31","author":"Brito-Zeron","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"R26-9-20210128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejim.2013.10.005","article-title":"Immunological profiles determine neurological involvement in Sjogrens syndrome.","volume":"25","author":"Jamilloux","year":"2014","journal-title":"Eur J Intern Med"},{"key":"R28-9-20210128","doi-asserted-by":"crossref","first-page":"e84605","DOI":"10.1371\/journal.pone.0084605","article-title":"Neurological involvement in primary Sjogrens syndrome: a focus on central nervous system.","volume":"9","author":"Morreale","year":"2014","journal-title":"PLoS One"},{"key":"R29-9-20210128","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/ene.12033","article-title":"Headache in primary Sjogrens syndrome: a population-based retrospective cohort study.","volume":"20","author":"Tjensvoll","year":"2013","journal-title":"Eur J Neurol"},{"key":"R30-9-20210128","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1001\/jama.2013.278448","article-title":"Autoantibodies present before symptom onset in primary Sjogrens syndrome.","volume":"310","author":"Jonsson","year":"2013","journal-title":"JAMA"},{"key":"R31-9-20210128","first-page":"686","article-title":"Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjogrens syndrome.","volume":"30","author":"Retamozo","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"R32-9-20210128","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/rheumatology\/ket295","article-title":"Anti-SSA Ro52Ro60 antibody testing by immunodot could help the diagnosis of Sjogrens syndrome in the absence of anti-SSASSB antibodies by ELISA.","volume":"52","author":"Mekinian","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"R33-9-20210128","first-page":"2480","article-title":"Anti52 kDa Ro, anti60 kDa Ro, and anti-La antibody profiles in neonatal lupus.","volume":"31","author":"Gordon","year":"2004","journal-title":"J Rheumatol"},{"key":"R34-9-20210128","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.semarthrit.2013.04.004","article-title":"Malignant lymphoma in primary Sjogrens syndrome: an update on the pathogenesis and treatment.","volume":"43","author":"Routsias","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"R35-9-20210128","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/acr.21887","article-title":"Risk of non-Hodgkins lymphoma in primary Sjogrens syndrome: a population-based study.","volume":"65","author":"Johnsen","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R36-9-20210128","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2013-203305","article-title":"Primary Sjogrens syndrome and malignancy risk: a systematic review and meta-analysis.","volume":"73","author":"Liang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R37-9-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jaut.2013.10.002","article-title":"Biomarkers of lymphoma in Sjogrens syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study.","volume":"51","author":"Quartuccio","year":"2014","journal-title":"J Autoimmun"},{"key":"R38-9-20210128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semarthrit.2013.03.001","article-title":"Clinical features distinguishing lymphoma development in primary Sjogrens Syndrome: a retrospective cohort study.","volume":"43","author":"Risselada","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"R39-9-20210128","doi-asserted-by":"crossref","first-page":"e59868","DOI":"10.1371\/journal.pone.0059868","article-title":"Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogrens syndrome: data at enrollment in the prospective ASSESS cohort.","volume":"8","author":"Gottenberg","year":"2013","journal-title":"PLoS One"},{"key":"R40-9-20210128","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jama.2010.1014","article-title":"Treatment of primary Sjogrens syndrome: a systematic review.","volume":"304","author":"Ramos-Casals","year":"2010","journal-title":"JAMA"},{"key":"R41-9-20210128","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrrheum.2012.53","article-title":"Topical and systemic medications for the treatment of primary Sjogrens syndrome.","volume":"8","author":"Ramos-Casals","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"R42-9-20210128","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","article-title":"Club Rhumatismes et Inflammations and the French Society of RheumatologyEfficacy of rituximab in systemic manifestations of primary Sjogrens syndrome: results in 78 patients of the AutoImmune and Rituximab registry.","volume":"72","author":"Gottenberg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R43-9-20210128","doi-asserted-by":"crossref","first-page":"R172","DOI":"10.1186\/ar4359","article-title":"Efficacy and safety of rituximab treatment in early primary Sjogrens syndrome: a prospective, multicenter, follow-up study.","volume":"15","author":"Carubbi","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"R44-9-20210128","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/art.37850","article-title":"Autoimmunity Centers of ExcellenceRituximab therapy for primary Sjogrens syndrome: an open-label clinical trial and mechanistic analysis.","volume":"65","author":"St Clair","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R45-9-20210128","doi-asserted-by":"crossref","first-page":"232","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sjogrens syndrome with rituximab: a randomized trial.","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"R46-9-20210128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2474-15-21","article-title":"TRACTISS trial teamThe TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjogrens syndrome.","volume":"15","author":"Brown","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"R47-9-20210128","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/rheumatology\/kes235","article-title":"The B-lymphocyte stimulator connection in Sjogrens syndrome.","volume":"52","author":"Ramos-Casals","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"R48-9-20210128","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaut.2013.04.005","article-title":"B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogrens syndrome.","volume":"51","author":"Nezos","year":"2013","journal-title":"J Autoimmun"},{"key":"R50-9-20210128","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sjogrens syndrome (open-label proof of concept ASAP study).","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R51-9-20210128","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/acr.22052","article-title":"Evaluation of histologic, serologic and clinical changes in response to abatacept treatment of primary Sjogrens syndrome: a pilot study.","volume":"65","author":"Adler","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R52-9-20210128","first-page":"954","article-title":"Is it time for biosimilars in autoimmune diseases Autoimmun R","volume":"12","author":"Cuadrado","year":"2013","journal-title":"ev"},{"key":"R53-9-20210128","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sjogrens syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogrens Syndrome (TRIPSS).","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:32:39Z","timestamp":1620948759000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201409000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000096","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}